Skip to content

Technology
Pipeline
About Us
News
Investors
Contact

Technology
Pipeline
About Us
News
Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 23 Results

March 25, 2026

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

March 16, 2026

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

March 9, 2026

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

March 9, 2026

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

February 20, 2026

Nasus Pharma to Participate in Upcoming Investor Conferences

February 17, 2026

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

February 13, 2026

Nasus Pharma Announces Closing of $15.0 Million Private Placement

February 10, 2026

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

12 3 »

IR Contact

Mike Moyer
LifeSci Advisors
617-308-4306
IR@nasuspharma.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Science

Technology
Pipeline
NS002 Epinephrine
NS001 Naloxone
Publications

Company

About us
Leadership
Board of Directors
Advisory Board
Contact

Investors

Investors Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
Investor FAQs

© 2026 Nasus Pharma All rights reserved

Accessibility Statement
Cookies Policy
Privacy Policy
Terms And Conditions Of Use

Scroll to Top